Delta-1: a global, multicenter, phase 2 study of Itil-168, an unrestricted autologous tumorinfiltrating lymphocyte (Til) cell therapy, in adult patients with advanced cutaneous melanoma
Authors
Gastman, B.Sarnaik, A.
Lawrence, D.
Olszanski, A.
Chmielowski, B.
Lutzky, J.
Butler, M.
Hamid, O.
Corrie, P.
Domingo-Musibay, E.
Thomas, S.
Thistlethwaite, Fiona C
Daniels, G.
Evans, T.
Furness, A.
Gibney, G.
Harries, M.
Medina, T.
Olson, D.
Pallan, L.
Whitman, E.
Wilson, M.
Aycock, J.
Hawkins, R.
Jiang, Y. Z.
Kennedy, A.
Robbins, P.
Roberts, Z.
Le Gall, J.
Affiliation
Cleveland Clinic, Cleveland, OH,Issue Date
2022
Metadata
Show full item recordCitation
Gastman B, Sarnaik A, Lawrence D, Olszanski A, Chmielowski B, Lutzky J, et al. Delta-1: A Global, Multicenter, Phase 2 Study of Itil-168, an Unrestricted Autologous Tumorinfiltrating Lymphocyte (Til) Cell Therapy, in Adult Patients with Advanced Cutaneous Melanoma. Journal for immunotherapy of cancer. 2022 Nov;10:A819-A. PubMed PMID: WOS:000919423400743.Journal
Journal for Immunotherapy of CancerDOI
10.1136/jitc-2022-SITC2022.0787Additional Links
https://dx.doi.org/10.1136/jitc-2022-SITC2022.0787Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/jitc-2022-SITC2022.0787